v3.26.1
Income Taxes
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Income Taxes

9. Income Taxes

The components of loss before income taxes were as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

United States

 

$

(154,535

)

 

$

(118,783

)

 

$

(143,256

)

Foreign

 

 

(75,380

)

 

 

(57,404

)

 

 

(117,176

)

Total loss before income taxes

 

$

(229,915

)

 

$

(176,187

)

 

$

(260,432

)

 

For the years ended December 31, 2025, 2024, and 2023, the Company recorded $52 thousand, $20 thousand, and $33 thousand of foreign current income tax expense, respectively.

Income taxes paid, net of refunds received, were not material for the years ended December 31, 2025, 2024, and 2023.

The tax effects of temporary differences that give rise to significant components of the deferred tax assets are as follows (in thousands):

 

 

 

December 31,

 

 

 

2025

 

 

2024

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

179,757

 

 

$

146,537

 

Intangible assets

 

 

11,891

 

 

 

11,902

 

Research and development tax credits

 

 

37,193

 

 

 

32,641

 

Stock-based compensation

 

 

32,708

 

 

 

27,904

 

Accruals

 

 

1,569

 

 

 

1,085

 

Operating lease liability

 

 

11,634

 

 

 

13,748

 

Sec. 174 Capitalized R&D

 

 

21,312

 

 

 

23,683

 

Total gross deferred tax assets

 

 

296,064

 

 

 

257,500

 

Valuation allowance

 

 

(288,065

)

 

 

(247,216

)

Net deferred tax assets

 

 

7,999

 

 

 

10,284

 

Deferred tax liabilities:

 

 

 

 

 

 

Operating lease right-of-use asset

 

 

(6,891

)

 

 

(8,822

)

Property and equipment

 

 

(1,108

)

 

 

(1,462

)

Total gross deferred tax liabilities

 

 

(7,999

)

 

 

(10,284

)

Total net deferred tax assets

 

$

 

 

$

 

 

The Company has recorded a full valuation allowance against its net deferred tax assets due to the uncertainty as to whether such assets will be realized. The net change in the total valuation allowance for the years ended December 31, 2025 and 2024, was an increase of approximately $40.8 million and a decrease of $126.3 million, respectively. The decrease in the year ended December 31, 2024 was due to the expiration of a foreign intangible asset.

As required under ASU 2023-09, the Company has included only the portion of the valuation allowance related to federal deferred tax assets in the “change in valuation allowance” line of the rate reconciliation. The following table presents a reconciliation of the total change in the valuation allowance (in thousands):

 

 

December 31,

 

 

 

2025

 

 

2024

 

Beginning balance

 

$

247,216

 

 

$

373,474

 

Change related to continuing operations

 

 

40,849

 

 

 

(126,258

)

Ending balance

 

$

288,065

 

 

$

247,216

 

NOLs and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (“IRS”) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company’s value immediately prior to the ownership change. The Company periodically completes a Section 382 analysis. Subsequent ownership changes since the most recent study may further affect the limitation in future years.

As of December 31, 2025, the Company had $224.3 million of federal and $616.3 million of state net operating loss available to offset future taxable income. A portion of the federal net operating loss carryforwards begin to expire in 2035 and the state net operating loss carryforwards begin to expire in 2035, if not utilized. $206.2 million of the federal net operating loss are not subject to expiration.

As of December 31, 2025, the Company also had federal and state research and development credit carryforwards of approximately $35.3 million and $11.5 million, respectively. The federal research and development credit carryforwards expire beginning 2035. The California tax credit can be carried forward indefinitely.

A reconciliation of the U.S. federal rate to the Company’s effective tax rate is as follows:

 

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

U.S. Federal statutory tax rate

 

$

(48,282

)

 

 

21.0

%

 

$

(36,999

)

 

 

21.0

%

 

$

(54,691

)

 

 

21.0

%

Change in valuation allowance

 

 

29,999

 

 

 

-13.0

%

 

 

18,175

 

 

 

-10.3

%

 

 

23,080

 

 

 

-8.9

%

Nontaxable or nondeductible items

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

4,382

 

 

 

-1.9

%

 

 

8,981

 

 

 

-5.1

%

 

 

10,704

 

 

 

-4.1

%

Other

 

 

137

 

 

 

-0.1

%

 

 

94

 

 

 

-0.1

%

 

 

77

 

 

 

0.0

%

Tax credits

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development tax credits

 

 

(3,235

)

 

 

1.4

%

 

 

(2,307

)

 

 

1.3

%

 

 

(3,776

)

 

 

1.4

%

Foreign tax effects

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Switzerland

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax rate differential

 

 

7,404

 

 

 

-3.2

%

 

 

5,260

 

 

 

-3.0

%

 

 

10,754

 

 

 

-4.1

%

Change in valuation allowance

 

 

9,527

 

 

 

-4.1

%

 

 

(145,138

)

 

 

82.4

%

 

 

11,061

 

 

 

-4.2

%

Intangible valuation

 

 

 

 

 

0.0

%

 

 

151,926

 

 

 

-86.2

%

 

 

2,258

 

 

 

-0.8

%

Other

 

 

120

 

 

 

-0.1

%

 

 

28

 

 

 

0.0

%

 

 

566

 

 

 

-0.3

%

Effective tax rate

 

$

52

 

 

 

0.0

%

 

$

20

 

 

 

0.0

%

 

$

33

 

 

 

0.0

%

 

The decrease in the intangible valuation in the year ended December 31, 2024 was due to the expiration of a foreign intangible asset.

The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. As of December 31, 2025, 2024 and 2023, none of the unrecognized tax benefits would affect income tax expense with consideration of the valuation allowance. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

The beginning and ending unrecognized tax benefits amounts are as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Unrecognized tax benefits at beginning of period

 

$

8,803

 

 

$

8,245

 

 

$

7,578

 

Increases related to current year tax positions

 

 

840

 

 

 

558

 

 

 

667

 

Unrecognized tax benefits at end of period

 

$

9,643

 

 

$

8,803

 

 

$

8,245

 

 

The Company files income tax returns in the United States and Switzerland. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All U.S. tax returns remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits.

On July 4, 2025, bill H.R. 1, known as the One Big Beautiful Bill Act (the “OBBBA”), was signed into law. The OBBBA revises U.S. corporate income tax laws by, among other things, restoring the option for immediate tax deductibility of domestic R&D expenditures, making permanent a 100% bonus depreciation deduction for property acquired domestically and providing a new provision for immediate expensing of manufacturing facility costs. The OBBBA did not have a material impact on the Company’s consolidated financial statements.